mCuMVTT-RBM induces higher antibody titers in comparison to SARS-CoV-2 convalescent sera
In comparison to infections with other viruses, patients infected with COVID-19 produce neutralizing antibodies at relatively low levels (27, 32). Hence, we compared the total RBD-specific IgG titer induced in mouse sera after vaccination with mCuMVTT-RBM to SARS-CoV-2 convalescent sera (total of 5 different sera). The results showed that the vaccine induces higher RBD-specific antibody titers even after a single priming dose compared to natural infection with SARS-CoV-2 and the booster injection further increased the RBD-specific antibody responses (Fig. 5A and B). Analysis of Area Under Curve (AUC) indicated a high difference (p <0.0001) between mouse sera collected on day 14 (after priming) or day 42 (after boost) to convalescent sera (Fig. 5C and D).